Healius share price on watch as FY20 results hit guidance

The Healius Ltd (ASX: HLS) share price is on watch as COVID-19 boosted pathology earnings but the board scrapped its final dividend

| More on:
changing asx share price represented by hand arranging wooden blocks that spell update

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Healius Ltd (ASX: HLS) share price is one to watch today after the Aussie healthcare group reported full-year results in line with guidance.

Why is the Healius share price worth watching?

For the year ended 30 June 2020 (FY20), Healius reported a 2.2% increase in underlying revenue to $1,600.4 million.

Underlying earnings before interest and tax (EBIT) fell 18.4% lower to $102.7 million. That saw underlying net profit after tax (NPAT) from continuing operations fall 21.2% lower to $55.4 million.

Both of these figures were in line with Healius' 27 July 2020 trading update with underlying NPAT in line with its mid-March guidance.

The coronavirus pandemic did weigh on earnings but strong pathology trading and subsequent initiatives underpinned the result. That strong pathology performance was aided by COVID-19 testing which is increasing in FY21.

Healius also booked a $142.5 million loss relating to the in-year impart of its Healius Primary Care business, largely relating to goodwill.

The company also reported strong performance up to March 2020 across its Pathology, Imaging and Montserrat Day Hospitals.

FY20 operating cash flow was up on FY19 figures to $153.4 million despite COVID-19. That saw the company's net debt position improve to $666 million with $424 million in liquidity.

What's happening with the final dividend?

Despite some strong earnings, the board declined to pay a full-year dividend. That makes the Healius share price worth watching as investors consider the capital management decision.

The first half dividend of 2.6 cents per share has been delayed due to COVID-19 until October.

Healius decided it was "not considered appropriate" given the assistance received. That includes significant government support, with other ASX companies coming under pressure this August.

An out-of-cycle dividend will be considered as part of a capital structure review following the Healius Primary Care sale.

Trading update

In a good sign for the Healius share price, the company reported a strong start to FY21.

Pathology revenues were up by 25% in July compared to last year thanks to significant community COVID-19 testing. Pathology has commercial contracts for COVID-19 screening with entities like the Federal Government and the AFL.

Imaging revenues were down 4% from July 2019 with further declines in August. Day Hospital has started the year strongly with Montserrat revenue up 27% compared to July 2019 and Adora Fertility up more than 50%.

Healius Primary Care revenues were up 7.5% on pcp with the dental business now recording results to receive the earn-out on completion of the Healius Primary Care sale.

Outlook

Management did cite a "strong outlook" for FY21 largely underpinned by the pathology business.

The board expects regular dividends to recommence in the first half of next year which is good news for the Healius share price.

Healius will provide a further trading update on 22 October when it holds its annual general meeting.

Should you invest $1,000 in Clinuvel Pharmaceuticals right now?

Before you buy Clinuvel Pharmaceuticals shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Clinuvel Pharmaceuticals wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Healthcare Shares

Pro Medicus shares climb 33% in less than a month, have I missed the dip?

Pro Medicus shares have soared. Is it the right time to invest?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Healthcare Shares

Why is this ASX All Ords stock surging 14% today?

This stock is starting the week strongly. But why? Let's find out.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »